Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Intra-Cellular Therapies Future Uncertain Following Schizophrenia Drug Study Failure

Intra-Cellular Therapies Future Uncertain Following Schizophrenia Drug Study Failure

The "placebo ate my clinical trial" excuse doesn't make sense, which places Intra-Cellular's plan to seek marketing approval for its schizophrenia drug in serious jeopardy.

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.

Amgen Multiple Myeloma Drug Kyprolis Fails to Help Newly Diagnosed Patients

Amgen Multiple Myeloma Drug Kyprolis Fails to Help Newly Diagnosed Patients

Amgen's effort to improve disappointing sales of its multiple myeloma drug Kyprolis took a hit Tuesday with the failure of a phase III clinical trial involving newly diagnosed patients.

Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next

Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next

Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

Failure is very profitable for Pain Therapeutics CEO Remi Barbier.